Recursion Pharmaceuticals, Inc. (RXRX) — SEC Filings
Recursion Pharmaceuticals, Inc. (RXRX) — 50 SEC filings. Latest: 8-K (Dec 8, 2025). Includes 25 8-K, 7 SC 13G/A, 6 10-Q.
View Recursion Pharmaceuticals, Inc. on SEC EDGAR
Overview
Recursion Pharmaceuticals, Inc. (RXRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 26, 2025: Recursion Pharmaceuticals, Inc. filed an 8-K on November 26, 2025, reporting on other events and financial statements. The filing details the company's principal executive offices located at 41 S Rio Grande Street, Salt Lake City, UT 84101, and its telephone number (385) 269-0203. The company was in
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bearish, 47 neutral, 1 mixed. The dominant filing sentiment for Recursion Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Recursion Pharmaceuticals, Inc. (RXRX) has filed 25 8-K, 6 10-Q, 3 8-K/A, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 4 DEFA14A, 1 SC 13G with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of RXRX's 38 recent filings, 2 were flagged as high-risk, 15 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $39,143,000 |
| Net Income | $-536,600,000 |
| EPS | N/A |
| Debt-to-Equity | 0.34 |
| Cash Position | $659,836,000 |
| Operating Margin | N/A |
| Total Assets | $1,399,526,000 |
| Total Debt | $352,578,000 |
Key Executives
- Dr. Blake W. Johnson
- Dr. Laura A. Perry
- Dr. Amy Abernethy
- Dr. Laura LaVoie
- Dr. Christopher Gibson
- Dr. Laura R. Fong
- Dr. Amy Schulman
- Dr. Christopher R. Palmer
- Amy Abernethy, M.D., Ph.D.
- Amy Reilly
- Christopher Gibson
Industry Context
Recursion Pharmaceuticals operates in the highly competitive and capital-intensive biotechnology and pharmaceutical sector, specifically focusing on the TechBio niche. This industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Companies in this space often rely on substantial external funding to advance their drug pipelines, facing pressure to demonstrate clinical efficacy and commercial viability.
Top Tags
sec-filing (6) · filing (5) · 8-K (4) · Biotechnology (4) · corporate-governance (4) · proxy-statement (4) · regulatory-filing (3) · 8-k (3) · amendment (3) · personnel (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Filing Date | 2025-11-26 | The date the 8-K was filed with the SEC. |
| Fiscal Year End | 1231 | Indicates the end of Recursion Pharmaceuticals' fiscal year. |
| Net Loss | $536.6M | Increased from $284.8M in 2024 for the nine months ended September 30, 2025, indicating widening losses. |
| Research and Development Expenses | $379.3M | Increased from $216.1M in 2024 for the nine months ended September 30, 2025, reflecting significant investment. |
| Total Revenue | $39.1M | Decreased from $54.3M in 2024 for the nine months ended September 30, 2025, showing a decline in operating revenue. |
| Accumulated Deficit | $2.0B | Increased from $1.4B at December 31, 2024, highlighting substantial historical losses. |
| Cash and Cash Equivalents | $659.8M | Increased from $594.4M at December 31, 2024, partly due to equity financing. |
| Proceeds from Common Share Issuances | $395.5M | Net proceeds for the nine months ended September 30, 2025, indicating significant equity dilution. |
| Shares Outstanding | 491.8M | Increased from 396.8M at December 31, 2024, reflecting share issuances and dilution. |
| Class A Shares Issued for Asset Acquisition | $20.3M | Non-cash transaction for the nine months ended September 30, 2025, indicating strategic asset growth. |
| Cost of Revenue (Q3 2025) | $14.7M | Increased from $12.1M in Q3 2024, indicating higher costs associated with revenue generation. |
| Research and Development (Q3 2025) | $121.1M | Increased from $74.6M in Q3 2024, showing continued acceleration of R&D investment. |
| Q2 2025 Total Revenue | $10.1M | Increased 94.2% from $5.2M in Q2 2024 |
| Q2 2025 Net Loss | $105.3M | Widened from $98.7M in Q2 2024 |
| Six-Month 2025 Total Revenue | $19.5M | Increased 89.3% from $10.3M in 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Recursion Pharmaceuticals, Inc. (RXRX)?
Recursion Pharmaceuticals, Inc. has 50 recent SEC filings from Feb 2024 to Dec 2025, including 25 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RXRX filings?
Across 50 filings, the sentiment breakdown is: 2 bearish, 47 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Recursion Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Recursion Pharmaceuticals, Inc. (RXRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Recursion Pharmaceuticals, Inc.?
Key financial highlights from Recursion Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RXRX?
The investment thesis for RXRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Recursion Pharmaceuticals, Inc.?
Key executives identified across Recursion Pharmaceuticals, Inc.'s filings include Dr. Blake W. Johnson, Dr. Laura A. Perry, Dr. Amy Abernethy, Dr. Laura LaVoie, Dr. Christopher Gibson and 6 others.
What are the main risk factors for Recursion Pharmaceuticals, Inc. stock?
Of RXRX's 38 assessed filings, 2 were flagged high-risk, 15 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Recursion Pharmaceuticals, Inc.?
Forward guidance and predictions for Recursion Pharmaceuticals, Inc. are extracted from SEC filings as they are enriched.